These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9081960)

  • 41. Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves.
    Gips M; Soback S
    J Vet Pharmacol Ther; 1996 Apr; 19(2):130-4. PubMed ID: 8735421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacokinetics of pefloxacin in burn patients].
    Potel G; Meignier M; Touzé MD; Montay G; Drugeon HB; Baron D
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):777-80. PubMed ID: 3309814
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures.
    Park SC; Yun HI; Oh TK
    J Vet Med Sci; 1996 Oct; 58(10):1039-40. PubMed ID: 8916010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep.
    González F; San Andrés MI; Nieto J; San Andrés MD; Waxman S; Vicente ML; Lucas JJ; Rodríguez C
    J Vet Pharmacol Ther; 2001 Aug; 24(4):241-5. PubMed ID: 11555178
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative studies on the pharmacokinetics of norfloxacin in chickens, turkeys and geese after a single oral administration.
    Laczay P; Semjén G; Nagy G; Lehel J
    J Vet Pharmacol Ther; 1998 Apr; 21(2):161-4. PubMed ID: 9597656
    [No Abstract]   [Full Text] [Related]  

  • 46. The in vitro liberation and the bioavailability of different brands of griseofulvin in plasma and urine in man.
    Terhaag B; Le Petit G; Pachaly C; Feller K
    Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):475-9. PubMed ID: 4055158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Absorption of ciprofloxacin and norfloxacin when administered as niosome-encapsulated inclusion complexes.
    D'Souza SA; Ray J; Pandey S; Udupa N
    J Pharm Pharmacol; 1997 Feb; 49(2):145-9. PubMed ID: 9055185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review of the bioavailability and pharmacokinetics of oral norfloxacin.
    Stein GE
    Am J Med; 1987 Jun; 82(6B):18-21. PubMed ID: 3300308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Diffusion of norfloxacin in epididymal tissue].
    Blondin C; Costa P; Bressolle F; Galtier M
    Pathol Biol (Paris); 1991 May; 39(5):520-3. PubMed ID: 1881687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Norfloxacin disposition after sequentially increasing oral doses.
    Swanson BN; Boppana VK; Vlasses PH; Rotmensch HH; Ferguson RK
    Antimicrob Agents Chemother; 1983 Feb; 23(2):284-8. PubMed ID: 6220672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improvement of norfloxacin oral bioavailability by EDTA and sodium caprate.
    Dos Santos I; Fawaz F; Lagueny AM; Bonini F
    Int J Pharm; 2003 Jul; 260(1):1-4. PubMed ID: 12818805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of milk on absorption of norfloxacin in healthy volunteers.
    Minami R; Inotsume N; Nakano M; Sudo Y; Higashi A; Matsuda I
    J Clin Pharmacol; 1993 Dec; 33(12):1238-40. PubMed ID: 8126259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly.
    Kelly JG; Deaney NB; Lavan J; Noel J
    Br J Clin Pharmacol; 1988 Dec; 26(6):787-90. PubMed ID: 3242584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment.
    Jungers P; Ganeval D; Hannedouche T; Prieur B; Montay G
    Eur J Clin Pharmacol; 1987; 33(5):463-7. PubMed ID: 3480804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits.
    Pavithra BH; Prakash N; Jayakumar K
    J Vet Sci; 2009 Dec; 10(4):293-7. PubMed ID: 19934593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative bio-availability characteristics of different brands of chloroquine available in Nigeria.
    Aderounmu AF; Fleckenstein L
    Afr J Med Med Sci; 1982 Jun; 11(2):61-6. PubMed ID: 6301244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog.
    Wallis SC; Charles BG; Gahan LR; Filippich LJ; Bredhauer MG; Duckworth PA
    J Pharm Sci; 1996 Aug; 85(8):803-9. PubMed ID: 8863267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats.
    Chenel M; Barbot A; Dupuis A; Mimoz O; Paquereau J; Bouquet S; Couet W
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1952-7. PubMed ID: 12760873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.
    Eandi M; Viano I; Di Nola F; Leone L; Genazzani E
    Eur J Clin Microbiol; 1983 Jun; 2(3):253-9. PubMed ID: 6224683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tissue distribution and binding to plasma proteins of norfloxacin nicotinate after intramuscular administration in pigs.
    Shem-Tov M; Ziv G; Gips M
    Zentralbl Veterinarmed B; 1994 Jun; 41(4):257-63. PubMed ID: 7839746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.